| アブストラクト | The GSK and Pfizer respiratory syncytial virus (RSV) vaccines are both indicated for adults aged 60 years and older, but only the Pfizer product is approved for use in pregnancy to prevent RSV-associated lower respiratory tract disease in infants aged younger than 6 months. To assess for vaccine administration errors (ie, administration of the GSK RSV vaccine to pregnant persons) VAERS (Vaccine Adverse Event Reporting System), a U.S. passive reporting system, was searched for the time period from August 2023 to January 2024. A total of 113 reports of these administration errors were identified. Most reports (103, 91.2%) did not describe an adverse event. These administration errors are preventable with proper education and training and other preventive measures. |
|---|
| ジャーナル名 | Obstetrics and gynecology |
|---|
| Pubmed追加日 | 2024/2/23 |
|---|
| 投稿者 | Moro, Pedro L; Gallego, Ruth; Scheffey, Anne; Fleming-Dutra, Katherine E; Hall, Elisha; Zhang, Bicheng; Marquez, Paige; Jones, Jefferson M; Nair, Narayan; Broder, Karen R |
|---|
| 組織名 | Immunization Safety Office, Division of Healthcare Quality Promotion, National;Center for Emerging and Zoonotic Infectious Diseases, and the Coronavirus and;Other Respiratory Viruses Division and the Immunization Services Division,;National Center for Immunization and Respiratory Diseases, Centers for Disease;Control and Prevention, Atlanta, Georgia; and the Office of Biostatistics and;Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food and;Drug Administration, Silver Spring, Maryland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38394669/ |
|---|
